NetworkNewsWire Editorial Coverage: The backbone of medical
advancement is biotechnology, an industry wrought with the
incredible potential of novel drug R&D, but vulnerable to the
risk of stringent regulatory approval processes. Within this
volatile market, however, is the cannabis-biotech sub-sector – a
market flourishing with opportunity, innovation, and deep roots of
medical possibilities. Fueled by an increasing volume of supportive
research, cannabis-based biotech companies are addressing large
markets of unmet medical need while rising to meet global demand of
epic proportion. Included among several companies in the
cannabis-biotech sub-sector is Lexaria Bioscience Corp.
(OTCQB: LXRP) (CSE: LXX) (LXRP
Profile), a company emerging as a
recognizable name within a space occupied by companies like
GW Pharmaceuticals PLC (NASDAQ: GWPH),
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE),
Insys Therapeutics, Inc. (NASDAQ: INSY) and
Axim Biotechnologies Inc. (OTCQB: AXIM).
Because the cannabis-biotech sub-sector remains in relative
infancy, it is full of uncharted territory and prospects as
companies aggressively explore the medicinal potential of marijuana
and the plant’s compounds and applications. Food bioscience company
Lexaria
Bioscience Corp. (OTCQB: LXRP) (CSE:
LXX), for instance, enjoys a unique position in this
sub-sector. As the only publicly traded company with a
cannabis-based intellectual portfolio that includes NSAIDs,
nicotine and vitamins, Lexaria has multiple patents pending in over
40 countries, and it recently received its first patents in the
U.S. and Australia relating to edible forms of cannabinoids
(http://nnw.fm/e8LvY).
At the center of these patents is the company’s proprietary
technology, which improves the delivery of bioactive compounds,
primarily cannabinoids, into the human body. While cannabinoids
tout great potential for medical treatment, the compounds are
poorly absorbed by the gastrointestinal tract. As a result, users
frequently turn to alternative administration methods, like
smoking, for enhanced effectiveness. Lexaria’s lipophilic
enhancement technology, however, demonstrates the ability to boost
bioavailability of orally-ingested cannabinoids while at the same
time masking their “unusual” taste. This technology is
patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids. Other patents are also pending for
tetrahydrocannabinol (THC), other psychoactive cannabinoids,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules.
In collaboration with the National Research Council of Canada
(“NRC”) (http://nnw.fm/fdG8Z), Lexaria has commenced lab work
to study and optimize the application of its technology toward
enabling the delivery of lipophilic active agents within foods,
beverages, capsules and other ingestible formats. Practical
applications of this collaboration could include expansion of
Lexaria's IP portfolio and the possibility of new commercial
arrangements. Lexaria currently has two distinct consumer brands
that utilize this game-changing technology of infusing hemp oil
inside the lipids in foods: ViPova™ and
Lexaria Energy.
Introduced in 2015, the ViPova product line began with a Chinese
black tea containing hemp oil infused into dried, evaporated nonfat
milk. The following year, Lexaria took advantage of the broader
beverage market, and ViPova’s product line was expanded to include
coffee and hot chocolate. The company sells its ViPova product
directly online to consumers.
Lexaria Energy products also utilize the company’s patented
infusion technology to deliver federally legal hemp oil ingredients
inside nutritious and tasty formulations that are free of the
bitter taste typically associated with hemp. Products in this line
include the Lexaria Energy Bar, a hemp oil-infused protein bar.
Other nutritious products are in development for the Lexaria Energy
line, with a focus on ensuring responsible production techniques
and gluten-free formulations.
Lexaria also licenses its technology to third-party partners,
making royalties an integral part of its overall business strategy
and revenue potential as it pursues opportunities to broaden and
strengthen its IP portfolio. Because Lexaria's technology relies on
a delivery methodology - and not just a single drug or molecule -
even cannabis giants like GW Pharmaceuticals PLC
(GWPH) might discover Lexaria's technology as an effective
way to deliver its drug.
GW Pharmaceuticals has become a world leader in developing
plant-derived cannabinoid therapeutics by leveraging its
established drug discovery and development processes, extensive
intellectual property portfolio, and regulatory and manufacturing
expertise. The company’s research delves into the potential
therapeutic applications of cannabinoids, and GW has evaluated the
pharmacology of various cannabinoids across a broad array of
disease areas. GW’s focus is chiefly on central nervous system
disorders, including epilepsy. The company’s lead product
candidate, Epidiolex, is a liquid formulation of pure plant-derived
CBD and is in development to treat various rare childhood-onset
epilepsy disorders. GW has also commercialized Sativex, the world’s
very first plant-derived cannabinoid prescription drug, which has
been approved in 29 countries outside the U.S. for the treatment of
multiple sclerosis-related spasticity. GW’s pipeline of other
cannabinoid product candidates includes compounds in development
for treating epilepsy, glioma and schizophrenia.
Another biotech standout in the cannabis market is
clinical-stage pharmaceutical company Zynerba
Pharmaceuticals, Inc. (ZYNE). Zynerba is focused on the
development of innovative transdermal synthetic cannabinoid
treatment options for patients with high unmet medical needs. The
company’s development pipeline includes two lead product candidates
that are being evaluated in five therapeutic indications: ZYN002
and ZYN001. Currently in phase 2 clinical development for
refractory epilepsy, osteoarthritis of the knee and Fragile X
syndrome, ZYN002 is the first and only synthetic form of CBD and
has been formulated as a patent-protected permeation-enhanced gel
for transdermal delivery into the circulatory system. ZYN001 is a
THC pro-drug that enables transdermal delivery through the skin and
into the circulatory system via a patch. A phase 1 clinical program
for fibromyalgia and peripheral neuropathic pain was initiated by
Zynerba in the first half of 2017.
Specialty pharmaceutical company Insys Therapeutics,
Inc. (INSY) is focused on developing and commercializing
innovative drugs and novel drug delivery systems for therapeutic
molecules with the end goal of improving quality of life for
patients. Insys uses proprietary sublingual spray technology along
with its pharmaceutical cannabinoid development capabilities to
address the clinical inadequacies of existing commercial products.
In May 2017, Insys Therapeutics received FDA approval for the final
product label of its Syndros (dronabinol) oral solution, marking
the last regulatory step needed before the official launch of the
product, which is planned to take place sometime in August 2017.
Syndros is a liquid formulation of the pharmaceutical cannabinoid
dronabinol and has been approved for use in the treatment of weight
loss-related anorexia in AIDS patients and nausea and vomiting in
chemotherapy patients who are unresponsive to conventional
antiemetic treatments. Insys is additionally at the phase 2
clinical development stage for a cannabidiol treatment to address
severe pediatric epilepsies.
Biotechnology company Axim Biotechnologies Inc. (OTCQB:
AXIM) is a leader in cannabinoid R&D and is striving
to set the green standard for cannabinoid bioscience. The company’s
most advanced program is its phase 2 clinical trial of CanChew Plus
chewing gum to treat irritable bowel syndrome. The company is
similarly using a chewing gum-based approach for the treatment of
pain, multiple sclerosis spasticity and other indications. CanChew
Gum is the world’s first patented, functional chewing gum that is
derived from CBD-rich industrial hemp, and it is legal in all 50
states. Axim is additionally conducting research into the use of
molecularly-modified cannabinoids as neuroprotectants, as well as
the use of industrial hemp-derived formulations of cannabigerol
(CBG) for dermatological applications. AXIM is further conducting
trials or has products in development targeting a large number of
indications, including ADHD, smoking cessation, ulcerative colitis,
Crohn’s disease, drug-related psychosis, psoriasis, atopic
dermatitis and more. The company is also in the process of
developing a unique extraction and freeze-drying technology for
producing molecularly/genetically-controlled pharma-grade
cannabinoids extracted from industrial hemp.
For biotech investors looking at the legal cannabis sector and
interested in potentially taking part of the growth in the broader
marijuana industry, the companies described above are all worth
keeping on your investment radar. Stay tuned to NetworkNewsWire for
more public information on investment opportunities and on Lexaria
Bioscience.
For more information on Lexaria Bioscience, please visit:
Lexaria
Bioscience Corp. (LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW are a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer's filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer's securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertake no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Aug 2024 to Sep 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Sep 2023 to Sep 2024